Etelcalcetide Found to Increase Bone Mineral Density in SHPT
Markers of bone resorption decreased in hemodialysis patients with 6 months of etelcalcetide treatment.
Markers of bone resorption decreased in hemodialysis patients with 6 months of etelcalcetide treatment.
Analyses demonstrated that an ABI of 1.79 correlated with radiographic evidence of calcified vessels.
Epoetin dose is significantly associated with cardiovascular disease whether patients had lower or higher hemoglobin levels, study finds.
In a study, IV iron was associated with twice the risk for infections in CKD.
In a study, patients receiving cinacalcet under supervision 3 times per week after dialysis rather than after daily self-administration showed improvement in their parathyroid hormone levels.
In a study, patients with uncontrolled SHPT were switched from oral cinacalcet to intravenous etelcalcetide.
Loss of renal function may not be the sole factor in SHPT development, according to new study findings.
A study of new dialysis patients showed that home hemodialysis was associated with a 23% decreased risk of death at 1 year compared with in-center hemodialysis.
A polymer that binds to hydrochloric acid in the GI tract and does not enter the systemic circulation significantly improved serum bicarbonate levels compared with placebo.
In a study of 933 individuals with a mean age of 78 years, higher serum uromodulin was associated with a lower risk of end-stage renal disease.